M&A Deal Summary

Impilo Acquires Scantox

On January 20, 2021, private equity firm Impilo acquired life science company Scantox

Acquisition Highlights
  • This is Impilo’s 3rd transaction in the Life Science sector.
  • This is Impilo’s 2nd transaction in Denmark.

M&A Deal Summary

Date 2021-01-20
Target Scantox
Sector Life Science
Buyer(s) Impilo
Deal Type Buyout (LBO, MBO, MBI)

Target

Scantox

Lille Skensved, Denmark
Scantox is a GLP (“Good Laboratory Practice”) accredited CRO, providing pre-clinical research services, including regulatory in-vivo toxicology studies, that are critical to any drug development process. Scantox was founded in 1977 and is based in Lille Skensved, Denmark.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

DESCRIPTION

Impilo is a private investment firm focused exclusively on on investments in Nordic companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo prefers majority investments, but will consider select minority situations. Target companies are generally valued between SEK 200 million and SEK 1.5 billion. Impilo has offices in Stockholm and Copenhagen.


DEAL STATS #
Overall 8 of 10
Sector (Life Science) 3 of 3
Type (Buyout (LBO, MBO, MBI)) 6 of 8
Country (Denmark) 2 of 4
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-15 Mallax Pharmaceuticals

Stockholm, Sweden

Mallax Pharmaceuticals is a pharma company ‘ready-to-use’ with required pharmaceutical processes and licenses. Mallax Pharmaceuticals was founded in 2020 and is based in Stockholm, Sweden.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-15 NutraQ

Oslo, Norway

NutraQ is a provider of subscription-based health and wellness products in the Nordic region. NutraQ was founded in 2002 and is based in Oslo, Norway.

Sell -